RT Journal Article
SR Electronic
T1 Pulmonary rehabilitation and changes in respiratory muscles, aerobic capacity and quality of life in Colombian patients with Interstitial Lung Disease
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3899
DO 10.1183/13993003.congress-2021.PA3899
VO 58
IS suppl 65
A1 Lina Marcela Orozco Mejía
A1 Alexandra López López
A1 Ricardo Mosquera
A1 Julián Andrés Rivera Motta
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3899.abstract
AB Introduction: Interstitial lung disease (ILD) is generated by a heterogeneous group of processes that affects the lung parenchyma, with significant morbidity and mortality. Physiopathologically, it compromises the compliance of the thorax and lung parenchyma, decreasing ventilation and gas exchange, causing fatigue and dyspnea, limiting activities of daily living with subsequent hospitalization. Pulmonary rehabilitation (PR) has shown to improve functional capacity and decrease symptoms, improving performance in activities of daily living.Objective: To identify changes in the strength of the respiratory muscles, exercise tolerance and quality of life in patients with ILD who attended PR.Materials and methods: Quasi-experimental study in patients with ILD for 8 weeks in PR, based on ATS/ERS 2013 guidelines; exercise tolerance, respiratory muscle strength and quality of life were evaluated. A paired T test was used and a value of p < 0.05 was considered as a significant difference.Results: 66 patients with ILD, mainly male, with a mean age of 63.5 ± 14.8 years. Table 1 describes the results in respiratory muscle strength, 6-minute walk test and quality of life (p <0.001).Conclusions: RP significantly improved exercise tolerance, respiratory muscle strength and quality of life. 6MWT 6-Minute Walk Test, MIP Maximal Inspiratory Pressure, MEP Maximal Expiratory Pressure, SGRQ Saint George's Respiratory Questionnaire PrePosp Value6MWT395,0454,8<0,001MIP-63,6-75,8<0,001MEP75,082,5<0,001 Symptoms SGRQ49,234,5<0,001Activity SGRQ63,256,3<0,001Impact SGRQ37,628,5<0,001Total SGRQ49,138,9<0,001FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3899.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).